Home » Newsletters » BioWorld

BioWorld

March 2, 1994

View Archived Issues

ALPHA THERAPEUTIC FILES IND

ACTIVIST GROUP PROTESTS MILK LABELING GUIDELINES

ISIS COMPLETES FINAL STAGE OF EQUITY FINANCING

EDITEK SECURES $1M CREDIT LINE

CSI'S CELL TRANSFER AIDS THERAPY ENTERS CLINICALS

APPOINTMENTS AND ADVANCEMENTS

LIDAK TO DEVELOP NEW N-DOCOSANOL INDICATIONS

HEMOSOL ACQUIRES STEM CELL TECHNOLOGY

GENENTECH'S PULMOZYME LAUNCHED IN U.K.

CYTOGEN ENTERS FINANCING AGREEMENT

MAGAININ RAISES $15.3M IN PIPE

NEUROCRINE COMPLETES $30M PRIVATE PLACEMENT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...